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Summary
 
We have recently shown that expression of the enzyme indoleamine 2,3-dioxygenase (IDO) dur-
ing murine pregnancy is required to prevent rejection of the allogeneic fetus by maternal T cells.
 
In addition to their role in pregnancy, IDO-expressing cells are widely distributed in primary
and secondary lymphoid organs. Here we show that monocytes that have differentiated under
 
the influence of macrophage colony-stimulating factor acquire the ability to suppress T cell pro-
liferation in vitro via rapid and selective degradation of tryptophan by IDO. IDO was induced
 
in macrophages by a synergistic combination of the T cell–derived signals IFN-
 
g
 
 and CD40-
ligand. Inhibition of IDO with the 1-methyl analogue of tryptophan prevented macrophage-
mediated suppression. Purified T cells activated under tryptophan-deficient conditions were
able to synthesize protein, enter the cell cycle, and progress normally through the initial stages
of G1, including upregulation of IL-2 receptor and synthesis of IL-2. However, in the absence
of tryptophan, cell cycle progression halted at a mid-G1 arrest point. Restoration of tryptophan
to arrested cells was not sufficient to allow further cell cycle progression nor was costimulation
via CD28. T cells could exit the arrested state only if a second round of T cell receptor signal-
ing was provided in the presence of tryptophan. These data reveal a novel mechanism by which
antigen-presenting cells can regulate T cell activation via tryptophan catabolism. We speculate
that expression of IDO by certain antigen presenting cells in vivo allows them to suppress un-
wanted T cell responses.
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C
 
ertain macrophages (Møs)
 
1
 
 and possibly other subsets
of APCs suppress T cell responses (1, 2). Immunosup-
pressive APCs have been hypothesized to play an important
role in maintaining peripheral T cell tolerance. We have
 
previously shown that Møs that differentiate in vitro
 
 
 
un-
der the influence of macrophage colony-stimulating factor
(MCSF) acquire the ability to suppress T cell proliferation
 
(3, 4). This attribute was not constitutively present but
rather was invoked only in response to attempted T cell ac-
tivation. Suppressor activity was restricted to specific Mø
phenotypes (e.g., the phenotype produced by MCSF), with
other phenotypes supporting normal T cell activation (3).
Taken together, these characteristics suggested that the in-
hibitory properties of MCSF-derived Møs might reflect a
physiologic system for regulating T cell activation. How-
ever, the mechanism of this inhibition was unknown.
In the course of our studies, we found that MCSF-derived
Møs were capable of rapidly and selectively depleting the
essential amino acid tryptophan from cocultures and that
this depletion occurred only in response to attempted T cell
activation. Møs are known to possess the inducible trypto-
 
phan-degrading enzyme indoleamine 2,3-dioxygenase (IDO),
 
which catalyzes the initial and rate-limiting step in the metab-
 
olism of tryptophan along the kynurenine pathway (5–8).
 
 
 
It
has been postulated that the role of IDO is to inhibit prolif-
eration of eukaryotic intracellular pathogens (9–13) or tu-
mor cells (14) by depriving them of tryptophan. At the
time of this study, however, no role had been proposed for
IDO in regulating T cell responses. Recently, we have re-
ported that IDO expression in placenta is critically involved
in preventing rejection of the allogeneic fetus by maternal
T cells (15). The current study tests the hypothesis that
tryptophan depletion via IDO is the mechanism by which
MCSF-derived Møs inhibit T cell activation in vitro and
identifies a tryptophan-sensitive cell cycle arrest point dur-
ing T cell activation.
 
1
 
Abbreviations used in this paper: 
 
CD40L, CD40 ligand; IDO, indoleamine
2,3-dioxygenase; Mø, macrophage; MCSF; macrophage colony-stimulat-
ing factor. 
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Materials and Methods
 
Reagents.
 
Recombinant human MCSF was the gift of Genet-
ics Institute, Cambridge, MA. Recombinant human IFN-
 
g 
 
was
the gift of Genentech, South San Francisco, CA. Recombinant
human CD40 ligand (CD40L) homotrimer was the gift of W.
Fanslow, Immunex Corp., Seattle, WA. The IDO inhibitor
1-methyl-
 
d
 
,
 
l
 
-tryptophan (16) was purchased from Aldrich Chem-
ical Co. 6-nitro-tryptophan (17) was synthesized by D. Boykin,
Georgia State University, Atlanta, GA, using a modification of
the method of Moriya et al. (18). Polyclonal antiserum against
human IFN-
 
g
 
 was obtained from Biosource International. All
other reagents were obtained from Sigma Chemical Co. unless
otherwise specified.
 
Cell Isolation and Culture. 
 
Human peripheral blood mono-
cytes and lymphocytes were isolated from healthy volunteer do-
nors by leukocytapheresis and counterflow centrifugal elutriation,
following appropriate informed consent under a protocol ap-
proved by our Institutional Review Board. Monocytes (
 
.
 
95%
purity by cell surface markers) were cultured in 96-well plates as
previously described (4) using RPMI 1640 with 10% newborn
calf serum (Hyclone) plus MCSF (200 U/ml).
T cell activation studies in cocultures were performed as previ-
ously described (4), using the above medium supplemented with
an additional 5% FCS. In brief, Møs (5 
 
3
 
 10
 
4
 
 cells/well) were al-
lowed to differentiate for 4–6 d in MCSF, and then autologous
lymphocytes (2 
 
3
 
 10
 
5
 
 cells/well) were added along with mito-
gen. The mitogens used in this study were anti-CD3 mAb (100
ng/ml, clone OKT3; American Type Culture Collection) and
staphylococcal enterotoxin B (5 
 
m
 
g/ml; Sigma Chemical Co.).
Both gave equivalent results; the data shown are from anti-CD3
unless otherwise specified. T cell proliferation was assessed by
standard thymidine incorporation assay as described (3). When
T cell activation was studied without Møs, fresh autologous
monocytes were added (1:4) as nonsuppressive accessory cells.
Conditioned medium from cocultures of T cells and Møs was
prepared by harvesting supernatant 48 h after T cell addition.
Conditioned medium was then used to support a second round
of T cell activation. Mitogen and other additives were prepared
in tryptophan-free buffers.
A chemically defined, serum-free medium (19) selectively de-
ficient in tryptophan was prepared using tryptophan-free RPMI
1640 (Select-amine kit; GIBCO BRL) supplemented with in-
sulin (10 
 
m
 
g/ml), iron-saturated transferrin (5 
 
m
 
g/ml), and BSA
(1 mg/ml ultra-pure grade; measured concentration of free trypto-
phan 
 
,
 
5 nM). Preliminary validation experiments confirmed that
T cell proliferation in this medium was undetectable but was
comparable to serum-based medium when tryptophan was
added. To study T cells in the absence of Møs, T cells were acti-
vated using anti-CD3 mAb adsorbed onto plastic tissue culture
wells (0.5 
 
m
 
g/cm
 
2
 
 in bicarbonate buffer, pH 9) plus soluble anti-
CD28 mAb (1 
 
m
 
g/ml; PharMingen).
 
Tryptophan and IDO Assays.
 
The tryptophan-degrading activ-
ity of Møs reflects a multifactored combination of IDO expres-
sion, tryptophan transport into the cells, and intracellular condi-
tions that posttranslationally affect enzyme activity (20). Therefore,
when tryptophan depletion was the outcome of interest, we mea-
sured the rate of disappearance of tryptophan from culture super-
natants over time. Tryptophan was assayed using the method of
Bloxam and Warren (21). Proteins were precipitated with 10%
TCA and free tryptophan assayed after conversion to norharman
using formaldehyde and FeCl
 
3
 
. The reaction product was mea-
sured spectrofluorometrically (excitation 360 nm, emission 460
nm) and compared against a standard preparation of tryptophan.
 
Validation studies showed this assay to be linear in the range of
0.1–100 
 
m
 
M, with an estimated threshold sensitivity of 0.05 
 
m
 
M.
Where it was desirable to show that tryptophan depletion in
cultures was due to IDO activity, culture supernatants were as-
sayed by HPLC for the presence of kynurenine. IDO catalyzes
the oxidation of tryptophan to 
 
N
 
-formylkynurenine, which in
Møs is rapidly converted into kynurenine (22) and then to other
downstream metabolites (7). With the exception of tryptophan
oxygenase, which is found only in hepatocytes, IDO is the only
enzyme capable of degrading tryptophan along the kynurenine
pathway (8). Thus, the appearance of kynurenine in cultures was
unambiguous evidence of functional IDO activity. However, be-
cause kynurenine can be converted into other downstream me-
tabolites, this assay was not quantitative. Where quantitative data
were required, the tryptophan depletion assay described above
was used.
HPLC assays were performed by the Medical College of
Georgia Molecular Biology Core Facility. Samples were prepared
by extracting 150 
 
m
 
l culture supernatant with 1 ml methanol.
Precipitated proteins were removed by centrifugation and the su-
pernatant dried under vacuum. Samples were resuspended in 100 
 
m
 
l
initial mobile phase (deionized water) and an aliquot injected
onto a C-18 column (Phenomenex Luna C-18; 250 
 
3
 
 4.6 mm;
5 
 
m
 
m). Samples were eluted with a linear gradient of acetonitrile
in water (0–80% over 20 min), and absorbance was measured at
254 nm. Standards for tryptophan, kynurenine, and 1-methyl-
tryptophan were run with each assay to establish retention times.
In preliminary validation studies, the identity and purity of each
peak was confirmed by mass spectroscopy.
 
Protein Synthesis and Amino Acid Analysis.
 
Total protein syn-
thesis was measured as incorporation of tritiated leucine (4 
 
m
 
Ci/ml)
over 24 h. TCA-insoluble proteins were precipitated and washed
three times in 5% TCA, and the precipitate was analyzed by liquid
scintillation counting. Amino acid concentrations in culture su-
pernatants were measured by HPLC in our clinical Neonatal Nu-
trition Laboratory.
 
RT-PCR.
 
Møs were harvested with EDTA and total RNA
prepared. Sample RNA (1 
 
m
 
g) was reverse transcribed with avian
myeloblastosis virus (AMV)-RT, and a 182-bp fragment amplified
with the following primers: forward, bp 237–254 of the pub-
lished sequence (23); reverse, bp 402–418, spanning exons 3–4.
Product formation was assessed by agarose gel electrophoresis and
ethidium bromide staining. PCR product was isolated from the
gel and reamplified with internal primers to confirm specificity.
 
Flow Cytometry.
 
Two-color FACS
 
®
 
 analysis was performed
using directly conjugated mAbs as previously described (24). T
lymphocytes were identified by gating on CD3-positive cells, and
expression of CD69, CD25, and CD71 was measured in the sec-
ond color.
 
Statistics.
 
Experiments for all figures were replicated at least
three times, and representative data are shown. Data points were
measured in triplicate and the mean reported. Error bars show
standard deviation. Where SD was 
 
,
 
10%, error bars have been
omitted for clarity. Comparisons of multiple groups within a sin-
gle experiment were by ANOVA.
 
Results
 
Cocultures of Møs and T Cells Are Selectively Depleted of
Tryptophan.
 
Supernatants were harvested from cocultures
of Møs and mitogen-activated T cells after 48
 
 
 
h. Fresh 
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lymphocytes were suspended in conditioned medium and
activated with additional mitogen. Fig. 1 shows that condi-
tioned medium completely failed to support T cell prolifer-
ation (
 
,
 
1% of the proliferation in fresh medium). How-
ever, the addition of tryptophan to conditioned medium
fully restored its ability to support T cell proliferation, indi-
cating that tryptophan was the only component that had
been depleted. Consistent with this finding, amino acid
analysis of conditioned media showed that all other es-
sential amino acids were present, and only tryptophan was
undetectable (data not shown). Titration of reagent trypto-
phan into conditioned medium gave a half-maximal con-
centration for T cell proliferation of 0.5–1 
 
m
 
M (Fig. 2),
compared with a measured concentration of tryptophan in
coculture-conditioned medium of 
 
,
 
50 nM (the detection
limit of our assay). Control-conditioned media from Møs
alone, from cocultures of Møs 
 
1
 
 T cells without mitogen,
or from T cells activated with fresh monocytes instead of
Møs all supported T cell proliferation comparably to fresh
medium (90–140% of control;
 
 n 
 
5 
 
3–4/group).
 
Expression of IDO by MCSF-derived Møs.
 
The kinetics of
tryptophan elimination were measured by coincubating
Møs and T cells with mitogen for 24 h to allow upregula-
tion of the tryptophan depletion pathway and then adding
fresh tryptophan and following its disappearance. As shown
in Fig. 3 A, tryptophan was eliminated by first-order kinet-
ics with a half-life of 2–3 h. The initial rate of elimination
when tryptophan was not limiting was up to 20,000 pmol/
10
 
6 
 
cells/h. This far exceeded the consumption attributable
to cellular metabolism (see control, Fig. 3 A), as Møs with-
out activated T cells depleted tryptophan at a rate of 300 
 
6
 
130 pmol/10
 
6 
 
cells/h (cumulative measurement obtained
over 7 d; data not shown). This implied that the majority
of tryptophan depletion by activated Møs was due to an in-
ducible system, which we suspected was IDO.
Consistent with this finding, abundant IDO mRNA was
detectable by RT-PCR in Møs after activation, whereas
before activation, IDO message was undetectable (Fig. 3 B).
To confirm the presence of IDO activity, culture superna-
tants were assayed for kynurenine. As shown in Fig. 3 C,
depletion of tryptophan was accompanied by a correspond-
ing increase in kynurenine production, confirming the pres-
ence of functional IDO activity.
 
Inhibition of IDO Prevents Mø-mediated Suppression of T
Cells.
 
We next asked whether pharmacologic inhibition
of IDO could prevent suppression of T cells in cocultures.
Figure 1. Coculture-condi-
tioned medium is selectively de-
pleted of tryptophan.  Human
monocytes were allowed to dif-
ferentiate for 5 d in MCSF. Then,
T cells were added and activated
with anti-CD3 mAb. Condi-
tioned medium was harvested
from cocultures after 48 h and
then used to support a second
round of activation with fresh T
cells. Replicate cultures were sup-
plemented with individual amino
acids to the concentrations nor-
mally found in RPMI 1640. Con-
trol cultures received either fresh
medium (CTL) or no supple-
ment (PBS). Proliferation was
measured by thymidine incorpo-
ration after 72 h.
Figure 2. Dose–response rela-
tionship to tryptophan for T cell
proliferation. Tryptophan was ti-
trated in coculture-conditioned
medium (prepared as described in
Fig. 1) and proliferation of T cells
measured after 72 h.
Figure 3. Elimination kinetics of
tryptophan in cocultures and expression
of IDO by MCSF-derived Møs.  (A)
MCSF-derived Møs were cultured for
24 h with autologous T cells, either with
(d) or without (j) anti-CD3 mAb. The
medium was then replaced with fresh
medium and supernatant from replicate
cultures harvested at the times shown. Tryptophan concentration was as-
sayed spectrofluorometrically as described in Materials and Methods. (B)
IFN-g–inducible IDO mRNA in MCSF-derived Møs. RT-PCR show-
ing IDO expression in MCSF-derived Møs before (lane 4) and after (lanes
1–3) activation for 24 h with recombinant IFN-g. Starting RNA for the
reverse transcriptase reaction in lanes 1–3 was from 20,000, 2000, and 200
activated Møs, respectively, and from 20,000 unactivated Møs in lane 4.
Lane 5 shows amplification of human IDO plasmid template giving the
expected 182-bp product. (C) HPLC analysis of Mø culture supernatants
showing degradation of tryptophan and production of kynurenine.
MCSF-derived Møs were preactivated for 24 h with IFN-g to induce
IDO expression, and then the spent medium was replaced 90:10 with
fresh medium. Trace 1 shows the analysis of supernatant immediately af-
ter adding fresh medium (time 0); trace 2 shows the conditioned medium
24 h later. The number of Møs in these experiments was kept low so that
some tryptophan would be detectable at the end of the assay. The traces
shown represent the portion of the elution gradient between 28 and 42%
acetonitrile (minutes 7.00–10.50), during which kynurenine (K) and
tryptophan (T) appeared. The peak labels are positioned at the points at
which the purified standards eluted, which were within 63 s of the cor-
responding sample peak. Compounds present in culture medium that also
absorbed at OD254 (unlabeled peaks) were readily resolved from tryp-
tophan and kynurenine, and the T and K peaks were confirmed by mass
spectroscopy (see Materials and Methods). The experiment shown used
purified Møs activated with recombinant ligands; identical results were
obtained when Møs were activated in coculture with T cells plus mito-
gen. One of four experiments is shown. 
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The compound 1-methyl-tryptophan has been reported to
be a potent competitive inhibitor of IDO activity when
tested in vitro using purified enzyme (16, 17). To deter-
mine whether this agent could inhibit IDO activity in in-
tact Møs, we added 1-methyl-tryptophan to activated Mø
cultures. As shown in Fig. 4 A, the presence of 1-methyl-
tryptophan markedly reduced the degradation of trypto-
phan by Møs, and this was accompanied by a correspond-
ing inhibition of kynurenine production (e.g., compare the
ratio of tryptophan to kynurenine after 24 h in Fig. 3 C),
confirming that the target of the inhibitor was IDO.
Functionally, the addition of 1-methyl-tryptophan to co-
cultures abrogated the ability of Møs to suppress T cell prolif-
eration in a dose-dependent manner (Fig. 4 B). Although
this finding was consistent with the proposed role for IDO in
Mø-mediated suppression, it might in theory indicate an un-
anticipated immunostimulatory role for 1-methyl-tryptophan
itself. To exclude this possibility, we synthesized a second ana-
logue of tryptophan, 6-nitro-tryptophan, which has also been
reported to inhibit purified IDO enzyme in vitro (17). As
shown in Fig. 4 C, 6-nitro-tryptophan also prevented Mø-
mediated suppression in a dose-dependent fashion (Fig. 4 C).
Finally, we tested the effects of supplemental tryptophan on
suppression. As shown in Fig. 4 D, high levels of tryptophan
did prevent suppression of T cells, provided that the number
of Møs in cocultures was kept low. At our usual concentra-
tions of Mø, it proved impossible to supplement with suffi-
cient tryptophan to overcome its rapid degradation. Thus, by
the use of two pharmacologic inhibitors of IDO and by tryp-
tophan supplementation, the mechanism of T cell suppression
in our system appeared to be depletion of tryptophan by IDO.
 
Tryptophan-degrading Activity Is Synergistically Induced by
Early Signals of T Cell Activation.
 
Møs did not degrade tryp-
tophan simply as a result of contact with T cells. Rather,
there was an obligate requirement that the T cells attempt to
activate (Fig. 3 A). In light of the existing studies implicating
IFN-
 
g
 
 as an inducer of IDO (25–27), we suspected that
IFN-
 
g 
 
from activating T cells might be the signal for IDO
induction. Consistent with this idea, low but detectable levels
of IFN-
 
g
 
 were present in cocultures within 4–6 h of T cell
activation, coincident with the time that tryptophan degrada-
tion began (Fig. 5 A). Neutralizing antibodies against IFN-
 
g
 
reduced the induction of tryptophan-degrading activity (Fig.
5 B) and reduced suppression of T cells by Møs (Fig. 5 C),
supporting a role for IFN-
 
g
 
 in the signaling pathway. How-
ever, the dose–response relationship using recombinant
IFN-
 
g
 
 revealed that relatively high concentrations of IFN-
 
g
 
were required for full induction of tryptophan-degrading ac-
tivity (Fig. 5 D). We therefore asked whether there was an
additional signal that might act in concert with IFN-
 
g
 
.
CD40L is upregulated early in T cell activation and is known
to act synergistically with IFN-
 
g
 
 to activate other Mø func-
tions (28). Fig. 5 D shows that CD40L exerted marked syn-
ergy with IFN-
 
g
 
, shifting the dose–response curve for IFN-
 
g
 
one to two orders of magnitude so that significant tryptophan
depletion began at IFN-
 
g
 
 concentrations of 
 
,
 
1 U/ml.
 
Effect of Tryptophan Deprivation on T Cell Protein and DNA
Synthesis.
 
We have previously shown that T cells acti-
vated in coculture with MCSF-derived Møs initially enter
the cell cycle but arrest before the first G1/S transition (4).
We therefore asked whether a comparable phenomenon
occurred when T cells were activated in the absence of
Figure 4. Inhibition of IDO activity prevents Mø-mediated suppression. (A) 1-methyl-tryptophan inhibits Mø
IDO enzyme activity. MCSF-derived Møs were activated with IFN-g for 24 h to induce IDO expression, and
then fresh medium was added as described in Fig. 3, along with 1-methyl-tryptophan (1 mM). Supernatants were
analyzed by HPLC for tryptophan (T) and kynurenine (K) immediately after the addition of fresh medium (trace
1) and 24 h later (trace 2). The 1-methyl-tryptophan peak (M) is off scale at the settings used. Control cultures for
these experiments (Møs with IFN-g but without 1-methyl-tryptophan) uniformly had .90% reduction in tryp-
tophan at hour 24, with a corresponding increase in kynurenine, as shown in Fig. 3. The experiment shown used
purified Møs activated with recombinant ligands; identical results were obtained when Møs were activated in co-
culture with T cells plus mitogen. (B) 1-methyl-tryptophan prevents T cell suppression in cocultures. T cells were
added to MCSF-derived Møs and activated with anti-CD3 mAb. Replicate cultures were treated with varying
concentrations of 1-methyl-tryptophan. Proliferation was measured after 72 h by thymidine incorporation. Controls (s) show proliferation by T cells
without Møs at the highest concentration of inhibitor used (there was no effect of inhibitor on T cells alone throughout the range of concentrations
shown). (C) A second inhibitor of IDO activity, 6-nitro-tryptophan, showed similar reversal of Mø-mediated inhibition of T cells. Experimental design
as in B. (D) Supplementation with high concentrations of tryptophan prevents Mø-mediated suppression. Møs were seeded at low density (CC-lo; 5 3
104 cells/well) and high density (CC-hi; 2 3 105 cells/well) and the medium supplemented with 53 the normal tryptophan concentration. Proliferation
was measured at hour 72. Controls show proliferation by Møs alone (M) and T cells alone (T). 
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tryptophan. Purified T cells (without monocytes or Møs)
were cultured in tryptophan-free medium using immobi-
lized anti-CD3 plus anti-CD28 mAb as activating stimuli.
In this system, T cells stimulated in the presence of trypto-
phan activated normally, whereas T cells stimulated with-
out tryptophan arrested before entry into the first S phase,
as shown by the complete absence of DNA synthesis (Fig. 6).
This arrest was not due to an absence of protein synthesis,
as T cells without tryptophan successfully upregulated CD69,
CD25 (high-affinity IL-2 receptor), and CD71 (transferrin
receptor) (Fig. 7) and secreted IL-2 and IFN-
 
g
 
 (Fig. 8), all
of which require new protein synthesis (29). Total protein
synthesis, measured as incorporation of radiolabeled leucine
during the first 24 h of activation, continued at a rate 40–
55% of controls (
 
n
 
 5 
 
3; see Materials and Methods), despite
the absence of exogenous tryptophan. Nonetheless, no en-
try into S phase occurred. Thus, T cells activated in the ab-
sence of exogenous tryptophan arrested in a fashion similar
to that which we had previously observed in coculture.
 
Identification of a Tryptophan-sensitive Arrest Point in
Mid-G1.
 
The upregulation of early G1 markers suggested
that some portion of G1 was tryptophan independent. To
test this hypothesis, T cells were activated for various times in
the absence of tryptophan, and then tryptophan was added
 
and the time to entry into S phase determined. Control
cells, cultured with tryptophan throughout, reproducibly en-
tered S phase 28–32 h after initial TCR engagement (times
are reported as 4-h ranges to reflect the limit of precision of
the assay). In contrast, T cells that had been preactivated
under tryptophan-free conditions required only 12–16 h to
enter S phase after tryptophan was added (Fig. 9 A), indi-
cating that significant progression through G1 had occurred
in the absence of tryptophan. The tryptophan-sensitive ar-
rest point was stable, with T cells surviving .72 h in the
absence of tryptophan with no loss of viability. When tryp-
tophan was added to arrested cells, the time of entry into
S phase was consistently 12–16 h, regardless of whether
cells had been preactivated for 36, 48, or 72 h without
tryptophan. This suggested that the arrest occurred at a spe-
cific point in G1 and that this position in the cell cycle was
maintained until tryptophan was restored.
From the preceding experiments, we estimated that the
tryptophan-independent portion of G1 was z14 h (calcu-
lated as the difference between the average time to S phase
for resting T cells versus the time to S phase for preacti-
vated cells). To test this estimate, we deprived T cells of
tryptophan during the initial 14 h of activation, then added
tryptophan just before the putative arrest point. As shown
in Fig. 9 B, cultures deprived of tryptophan for the first 14 h
entered S phase identically to T cells supplied with tryp-
tophan throughout, supporting the hypothesis that the ini-
tial portion of G1 was independent of tryptophan. In addi-
tional experiments (not shown), delaying the addition of
tryptophan beyond 14 h introduced a corresponding delay
in entry into S phase, supporting the proposed localization
of the arrest point close to hour 14.
T Cells Can Commit to Cell Division in the Absence of Tryp-
tophan. Resting (G0) T cells require TCR signaling in
order to enter G1, but subsequent progression through the
cell cycle rapidly becomes TCR independent (for a review
Figure 5. IFN-g and CD40L act synergistically to induce IDO. (A) MCSF-derived Møs were cocultured with T cells and anti-CD3 mAb. Following
lymphocyte addition, culture supernatants were harvested at the times shown and assayed for IFN-g (j, left axis) and tryptophan concentration (d, right
axis). (B) Møs and T cells were cocultured with mitogen in the presence of various concentrations of neutralizing anti–IFN-g antiserum. Tryptophan con-
centration in culture supernatants was determined after 18 h. A low density of Møs was used for these experiments so as not to obscure the effect of
IFN-g. (C) Møs were cultured at a range of seeding densities as shown, and then T cells and anti-CD3 mAb were added either with (j) or without (d)
neutralizing antibodies to IFN-g (100 neutralizing U/ml). Antibodies to IFN-g reduced the effectiveness of Møs in suppressing T cells, particularly when
the number of Møs was limiting. (D) MCSF-derived Møs were cultured for 24 h with various concentrations of recombinant IFN-g, either in the pres-
ence (j) or absence (m) of recombinant CD40L (500 ng/ml). At the end of the activation period, culture supernatants were assayed for the concentra-
tion of tryptophan remaining. The single round point shows tryptophan degradation in response to CD40L alone.
Figure 6. T cells do not enter
S phase in the absence of tryp-
tophan.  T cells were activated
with immobilized anti-CD3 mAb
plus anti-CD28, either in chemi-
cally defined tryptophan-free
medium (j) or in the same me-
dium supplemented with 25 mM
tryptophan (d). DNA synthesis
was assayed by thymidine incor-
poration at the times shown.1368 Regulation of T Cells by IDO
see reference 29). In our system, commitment to TCR-
independent cell division was first detectable z6 h after
TCR engagement, and most cells were committed by hour
12. As shown in Fig. 10, this commitment occurred identi-
cally regardless of whether tryptophan was present or ab-
sent during the relevant time period. As long as the cells
were not allowed to arrest (i.e., tryptophan was supplied
before the tryptophan-sensitive checkpoint), commitment
to cell division proceeded normally.
T Cells Reverse Their Commitment to Cell Cycle Progression
upon Entering the Arrested State.  In contrast to the experi-
ments shown in Fig. 10, however, once T cells entered the
arrested state, simply restoring tryptophan was no longer
sufficient to allow cell cycle progression. T cells were acti-
vated for 48 h in tryptophan-deficient medium using im-
mobilized anti-CD3/CD28. The arrested cells were then
removed from contact with anti-CD3, washed free of anti-
CD28, and transferred to medium containing normal levels
of tryptophan. As shown in Fig. 11, despite their previous
48-h exposure to anti-CD3, the arrested T cells still re-
quired additional TCR signaling plus the presence of tryp-
tophan to exit the arrested state. Even costimulation via
CD28 was not sufficient to promote cell cycle progression
in the absence of TCR engagement.
Discussion
In this study, we show that tryptophan catabolism via
IDO is the mechanism by which MCSF-derived Møs sup-
press T cell proliferation in vitro. We have recently tested
this hypothesis of IDO-mediated T cell suppression in vivo
Figure 7. Expression of activation markers on T cells deprived of tryp-
tophan. T cells were activated in tryptophan-free medium using immobi-
lized anti-CD3/CD28 (heavy trace), or cultured under identical condi-
tions but without anti-CD3/CD28 (light trace). At the times shown,
both groups were harvested and stained for expression of activation mark-
ers as described in Materials and Methods.
Figure 8. Production of IFN-g and IL-2 by T cells deprived of tryp-
tophan. T cells were activated with anti-CD3 mAb in tryptophan-free
medium (j) or in the same medium supplemented with 25 mM tryp-
tophan (d) and the concentration of IFN-g (A) and IL-2 (B) in culture
supernatants determined at the times shown.
Figure 9. T cells that have entered the tryptophan-sensitive arrested
state retain their position in mid-G1. (A) T cells were activated in tryp-
tophan-free medium using immobilized anti-CD3/CD28 (d). After a
period of preactivation (24–72 h with similar results; 48 h in the experi-
ments shown), tryptophan was added and the time to entry into S phase
determined (defined as the initiation of thymidine incorporation). Repli-
cate aliquots of cells were activated in tryptophan-containing medium
without the 48-h preincubation period (j). Lag time in each case was
defined as the time to initiation of S phase from the point at which cells
saw both tryptophan and anti-CD3. The arrow shows that the lag time to
S phase was shortened by 12–16 h due to preactivation in the absence of
tryptophan, suggesting that this portion of G1 had been accomplished be-
fore the point at which cells arrested. Representative of seven experi-
ments at 36, 48, and 72 h, all showing the same lag time to S phase. (B)
T cells were activated with anti-CD3/CD28 in the presence (j) or ab-
sence (d) of tryptophan. After 14 h (the time of the putative arrest point
estimated from A), tryptophan was added to the tryptophan-deficient cul-
tures and entry into S phase determined. T cells rescued at hour 14
showed no delay compared with controls.1369 Munn et al.
using the model of allogeneic pregnancy. This model was
chosen because it has long been recognized as paradoxical
that the maternal immune system tolerates a genetically for-
eign fetus throughout gestation (30). IDO is known to be
expressed in human placenta and has been reported to be
localized to the zone of contact between fetal-derived tis-
sues and the maternal immune system (31). Using 1-methyl-
tryptophan (described in Fig. 4) as a pharmacologic inhibi-
tor of IDO, we have demonstrated that IDO is a required
component of the mechanism by which the allogeneic fe-
tus protects itself from rejection by the maternal immune
system and that inhibition of IDO breaks maternal toler-
ance to the allogeneic fetus (15). In the same report, we also
showed that pharmacologic inhibition of IDO enhances
the activation of autoreactive T cells. Thus, by two mea-
sures—breaking tolerance and enhancing autoreactivity—
these data support a role for IDO in regulating T cell re-
sponses in vivo.
IDO has previously been viewed primarily as a host de-
fense mechanism, inhibiting proliferation of intracellular
pathogens (6, 9–13) or cancer cell lines (14) by depriving
them of tryptophan (for a review see reference 8). In these
settings, the proposed role of IDO has been to eliminate
the cell’s own stores of tryptophan. To our knowledge, no
role for IDO in regulating the proliferation of adjacent cells
has been suggested. However, both direct and indirect evi-
dence indicates that IDO is widely expressed throughout
the immune system (32, 33) and, specifically, that it is lo-
calized to a subset of cells with a Mø or dendritic cell mor-
phology (33–35). These IDO-expressing cells are found at
several putative sites of immune tolerance or privilege, in-
cluding thymus, mucosa of the gut, epididymis, placenta,
and the anterior chamber of the eye (32, 33, 36, 37). This
pattern of widespread expression throughout the immune
system is difficult to reconcile with a simple mechanism of
host defense. We hypothesize that IDO expression by APCs
functions to suppress undesirable T cell activation and thus
helps maintain peripheral tolerance.
Two models might be proposed by which IDO could
suppress T cells in vivo: it might catalyze the production of
a suppressive metabolite of tryptophan, or it could deplete
local tryptophan below some threshold level required for
T cell activation. In repeated experiments, we have been
unable to detect any evidence of an immunosuppressive
metabolite in coculture supernatants (Figs. 1 and 2) (4).
Furthermore, our experiments with isolated T cells imply a
specific checkpoint in early T cell activation that is sensitive
to low concentrations of tryptophan. For these reasons, we
favor the tryptophan depletion hypothesis.
Implicit in this hypothesis is the assumption that cells ex-
pressing IDO in vivo could create a local microenviron-
ment in which tryptophan is low, despite the availability of
ample tryptophan elsewhere. In this regard, it is well estab-
lished that delivery of a substrate into local microenviron-
ments is sharply limited by the rate of diffusion (Kd)
through the interstitial space (38, 39). In the face of even
normal metabolic demands, substrate concentrations rap-
idly fall to undetectable levels within a few cell diameters of
the source of delivery (39). Because the rate of tryptophan
consumption by IDO-expressing Møs is orders of magni-
tude greater than normal metabolic demands, it is plausible
that such Møs could create local conditions of very low
tryptophan concentrations. Although this hypothesis is now
speculative with regard to tryptophan, the phenomenon is
well documented with regard to, for example, the local hy-
poxic state created within muscle tissue during exercise.
Because tryptophan degradation by IDO is much greater
than consumption by metabolic demands (Fig. 3), it is likely
that IDO constitutes the major route of tryptophan deple-
tion by activated Møs. However, IDO could act in combi-
nation with other pathways. Møs have a high rate of pro-
tein synthesis, and the incorporation of free tryptophan
into proteins could contribute to local tryptophan deple-
tion. Indeed, the tRNA synthetase for tryptophan (the WRS
gene) is unique among tRNA synthetases in that it is mas-
sively induced in Mø lineage cell lines (but not lymphoid
lines) by the same signals that induce IDO (40). It has been
proposed that this induction allows Møs to compete prefer-
entially for tryptophan when the concentration of substrate is
low. Likewise, any pathway that transported tryptophan into
Møs, whether for protein synthesis, degradation by IDO, or
incorporation into other biosynthetic pathways, would also
serve to deplete local tryptophan. Thus, IDO could act in
concert with other catabolic pathways to render Møs an ef-
fective local “sink” for tryptophan.
The proposed tryptophan depletion model gains support
from the apparent existence of a cell cycle arrest point sen-
Figure 10. T cells undergo
normal commitment to TCR-
independent activation in the ab-
sence of tryptophan. T cells were
exposed to immobilized anti-
CD3/CD28 for 2–12 h in the
presence (light bars) or absence
(dark bars) of tryptophan. At the
times shown, cells were removed
from contact with anti-CD3. Af-
ter transfer, tryptophan was
added to the tryptophan-defi-
cient cultures, and all groups
were continued out to hour 48.
Cells were transferred in their own conditioned medium without wash-
ing and continued to receive anti-CD28 throughout. At hour 48, all
groups were assayed for proliferation by thymidine incorporation. The 2-h
time point (no proliferation after transfer) is included as a control to con-
firm that there was no carryover of anti-CD3 into the new cultures.
Figure 11. T cells require TCR
signaling to exit the arrested state.
T cells were activated for 48 h in
the absence of tryptophan using
immobilized anti-CD3/CD28.
To simulate loss of contact with
the APC, T cells were removed
from the immobilized anti-CD3,
washed, and returned to culture in
medium containing 25 mm tryp-
tophan. Upon replating, replicate
cultures received immobilized
anti-CD3, anti-CD28, or both.1370 Regulation of T Cells by IDO
sitive to tryptophan concentration. Although the absence
of any essential nutrient is, by definition, incompatible with
long-term proliferation, the arrest point we describe appears
more specific than simple protein starvation. First, although
protein synthesis is reduced in the absence of exogenous
tryptophan, it still occurs at a significant rate, presumably re-
flecting a combination of endogenous tryptophan stores and
recycling of tryptophan from catabolism of endogenous and
exogenous proteins (41). Yet despite ongoing protein syn-
thesis, cell cycle progression is not simply delayed but rather
is completely arrested. Second, the arrest induced by tryp-
tophan deprivation occurs at a reproducible point in the cell
cycle and remains stable once entered, suggesting a regulated
process. Taken together, these attributes suggest a specific,
tryptophan-sensitive cell cycle arrest point.
It has been noted by several groups that deprivation of
certain amino acids—tryptophan in particular—exerts an
inhibitory effect on cell cycle progression that cannot be
explained by the effect on protein synthesis (42–45). For
that reason, it has been suggested that levels of these amino
acids may function as specific checkpoints regulating cell cy-
cle progression. However, the biologic significance of such
amino acid–specific checkpoints and the mechanism by which
the levels of amino acids might be manipulated in order to
regulate T cell activation has remained obscure. We now
propose a system in which regulation of local tryptophan
concentration functions as a means of communication be-
tween APCs and T cells, with APCs regulating the trypto-
phan level via IDO and T cells responding with either acti-
vation or arrest, depending on the level they detect.
As a strategy to inhibit T cell activation, arresting pro-
gression through the cell cycle is not unique to tryptophan
metabolism. The immunosuppressive drugs mycopheno-
late, rapamycin, and leflunomide all induce a mid-G1 arrest
in activating T cells, and this is believed to account in
whole or part for their immunosuppressant action (46–48).
Recent evidence suggests that T cells require one or more
rounds of cell division to acquire a variety of effector func-
tions (49–51), so inhibiting proliferation may also inhibit
functional activity. In our system, it is currently unknown
how T cells sense the level of tryptophan and trigger cell
cycle arrest. Tryptophan-sensing systems in bacteria have
been well described (52), but comparable systems in eu-
karyotes have not yet been identified. However, mamma-
lian genes such as tryptophan oxygenase are known to be
regulated by changes in tryptophan levels (53), so such
sensing systems can be inferred to exist.
The requirement for a second signal from the TCR in
order to exit the arrested state is an important finding in
light of our proposed biologic model. Under this model,
T cells that attempt to activate while in contact with an
IDO-expressing APC are inhibited by the local absence of
tryptophan. In theory, however, once such T cells were
committed to cell division, they could migrate elsewhere
and complete the activation process under tryptophan-
sufficient conditions. The data presented in Fig. 11 show
that once T cells have arrested, simply regaining tryptophan
is no longer sufficient to allow continued activation. De-
spite the fact that T cells would normally have become in-
dependent of TCR signaling before the tryptophan-sensi-
tive checkpoint (Fig. 10), once they enter the arrested state
they apparently reverse this commitment and reimpose
upon themselves a requirement for a second round of TCR
signaling. From a biologic standpoint, this would mean that
a T cell arrested by an IDO-expressing APC would be
obliged to find a second, nonsuppressive APC presenting
the same antigen in order to exit the arrested state.
What would be the fate of an arrested T cell if no such
supportive APC could be found? In vitro, we find that ar-
rested cells undergo progressive apoptosis after several days
if not rescued by TCR engagement (4). Whether this means
that they would likewise die in vivo, enter some form of
anergy, or return to a resting state remains to be deter-
mined. However, the arrested state we describe differs from
classical anergy (54) in several interesting respects. First, the
cells retain their responsiveness to TCR engagement (Fig.
11). Second, costimulation via CD28 is not sufficient to
rescue cells once they arrest. And third, arrested cells die if
not rescued within a relatively brief window of time. Taken
together, these attributes suggest that T cells arrested by tryp-
tophan deprivation are not immediately deleted from the
repertoire but that they must find a permissive APC and
complete the activation process if they are to survive.
In conclusion, our hypothesis regarding the biologic
role of IDO-expressing APCs is that they are involved in
maintaining peripheral tolerance to self antigens. Our in
vitro model has focused on MCSF-derived Møs as one
example of immunosuppressive APCs, but dendritic cells
or other APCs that possess inducible IDO could likewise
be immunosuppressive. We speculate that tryptophan ca-
tabolism may constitute a previously unsuspected mecha-
nism contributing to the regulation of peripheral T cell
activation.
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